



Tanzania – Inactivated Polio Vaccine (IPV) Support
 This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Tanzania										
2. Grant Number: 1518-TZA-25c-X / 15-TZA-08h-Y										
3. Date of Decision Letter: 01 July 2014										
4. Date of the Partnership Framework Agreement: 01 July 2013										
5. Programme Title: NVS, IPV Routine										
6. Vaccine type: Inactivated Polio Vaccine (IPV)										
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID										
8. Programme Duration²: 2015 - 2018										
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): <i>Please note that endorsed or approved amounts for 2017 and 2018 will be communicated in due course, taking into account updated information on country requirements and following GAVI's review and approval processes.</i> <table border="1" style="margin: 10px auto; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 20%;"></th> <th style="width: 20%;">2015</th> <th style="width: 20%;">2016</th> <th style="width: 20%;">Total³</th> </tr> </thead> <tbody> <tr> <td style="text-align: left;">Program Budget (US\$)</td> <td>US\$5,252,500</td> <td>US\$4,278,500</td> <td>US\$9,531,000</td> </tr> </tbody> </table>		2015	2016	Total ³	Program Budget (US\$)	US\$5,252,500	US\$4,278,500	US\$9,531,000		
	2015	2016	Total ³							
Program Budget (US\$)	US\$5,252,500	US\$4,278,500	US\$9,531,000							
10. Vaccine Introduction Grant: US\$1,599,000										
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴ <table border="1" style="margin: 10px auto; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 70%;">Type of supplies to be purchased with GAVI funds in each year</th> <th style="width: 30%;">2015</th> </tr> </thead> <tbody> <tr> <td style="text-align: left;">Number of IPV vaccines doses</td> <td>4,388,400</td> </tr> <tr> <td style="text-align: left;">Number of AD syringes</td> <td>2,896,400</td> </tr> <tr> <td style="text-align: left;">Number of safety boxes</td> <td>31,875</td> </tr> <tr> <td style="text-align: left;">Annual Amounts (US\$)</td> <td>US\$5,252,500</td> </tr> </tbody> </table>	Type of supplies to be purchased with GAVI funds in each year	2015	Number of IPV vaccines doses	4,388,400	Number of AD syringes	2,896,400	Number of safety boxes	31,875	Annual Amounts (US\$)	US\$5,252,500
Type of supplies to be purchased with GAVI funds in each year	2015									
Number of IPV vaccines doses	4,388,400									
Number of AD syringes	2,896,400									
Number of safety boxes	31,875									
Annual Amounts (US\$)	US\$5,252,500									
12. Procurement agency: UNICEF.										

¹ Please refer to section 18 for additional on IPV presentation.

² This is the entire duration of the programme.

³ This is the total amount endorsed by GAVI for 2015 and 2016.

⁴ This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

13. Self-procurement: Not applicable.								
14. Co-financing obligations: GAVI's standard co-financing requirements do not apply to IPV. However, Tanzania is encouraged to contribute to vaccine and/or supply costs for IPV.								
15. Operational support for campaigns: N/A								
16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:								
<table border="1"> <tr> <td>Reports, documents and other deliverables</td> <td>Due dates</td> </tr> <tr> <td>Annual Progress Report or equivalent</td> <td>To be agreed with GAVI Secretariat</td> </tr> <tr> <td></td> <td></td> </tr> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or equivalent	To be agreed with GAVI Secretariat			
Reports, documents and other deliverables	Due dates							
Annual Progress Report or equivalent	To be agreed with GAVI Secretariat							
17. Financial Clarifications: Not applicable.								
18. Other conditions: If Tanzania envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in its initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Tanzania.								
	IRC Comments	Suggested Way Forward	Time Frame					
	Licensure is important for the introduction of new vaccines. Country should indicate if; and how the licensure requirements can be met in time for the planned introduction.	To confirm the exact licensure process and expected licensure date.	By July 31, 2014					

Signed by,
On behalf of the GAVI Alliance



Hind Khatib-Othman
 Managing Director, Country Programmes

01 July 2014